What factors might influence your initial treatment decision of oligometastatic NSCLC assuming good performance status, lack of actionable mutation, and PD-L1 status < 50%?

Would you consider "aggressive" concurrent chemoradiation followed by SRS to the CNS lesion and possible consolidative immunotherpay (the PACIFIC approach) or would you consider triplet with platinum-doublet/immunotherapy (Keynote-189 approach)?

Please select the option that best describes you:

What factors might influence your initial treatment decision of oligometastatic NSCLC assuming good performance status, lack of actionable mutation, and PD-L1 status < 50%?

Related Questions